

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/07705 A1

- (51) International Patent Classification⁷: **A61K 9/14**, 47/26, 31/58, 31/35, A61P 11/00
- (21) International Application Number: PCT/EP01/08395
- (22) International Filing Date: 19 July 2001 (19.07.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
1015751 20 July 2000 (20.07.2000) NL
- (71) Applicant (for all designated States except US): **CAMP-INA MELKUNIE B.V.** [NL/NL]; Hogeweg 9, NL-5301 LB Zaltbommel (NL).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **KUSSENDRAGER, Klass, Daniel** [NL/NL]; Eksterdonk 17, NL-5467 DN Veghel (NL). **ELLISON, Mark, Jason, Heath** [NL/NL]; Jan Heistraat 2a, NL-5211 TD 's Hertogenbosch (NL).
- (74) Agents: **VAN SOMEREN, Petronella, Francisca, Hendrika, Maria** et al.; Arnold & Siedsma, Sweelinckplein 1, NL-2517 GK The Hague (NL).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CARRIER MATERIAL FOR DRY POWDER INHALATION

(57) Abstract: The present invention relates to a carrier material for use in dry powder inhalation formulations, comprising carrier particles that are spherical in nature and contain no amorphous material. In addition the invention provides a method for the preparation of a carrier material for use in dry powder inhalation formulations, comprising the steps of providing a carrier base material consisting of sperical carrier particles; and crystallising the carrier base material in order to remove amorphous material present in the particles to obtain the carrier material.

WO 02/07705 A1

CARRIER MATERIAL FOR DRY POWDER INHALATION

The present invention relates to a carrier material for use in dry powder inhalation formulations, to the process for manufacture of these carrier materials and to dry powder inhalation formulations using the carrier materials.

Dry powder inhalers have been in existence since the late 1960's. Interest in this technique for delivering pharmacological active components to the lungs was initially limited due to the popularity of pressurized metered dose inhalers (pMDI's). However, since the decision to eliminate CFC's from pMDI's due to environmental issues, dry powder inhalers are becoming more popular.

Traditionally, formulations for dry powder inhalation comprise a pharmacologically active component and an inert carrier material, being in most cases α -lactose monohydrate crystals. The active component is usually micronised with a particle size less than 5 μm , to enable deposition in the lower levels of the lungs. The purpose of the inert carrier is to aid flow and to prevent the formation of agglomerates of the active component which agglomerates can not be dispersed, thus preventing deposition at the site of action.

It was however found that over time α -lactose does not have an optimal flow, which may lead to problems, such as clogging, in the inhaler. In addition, it was found that α -lactose monohydrate does not always lead to a 100% drug delivery. Ideally, upon inhalation of a dry powder inhalation formulation, the carrier hits the throat, after which the drug, which is in loose association with the carrier, detaches therefrom and is transported to the lungs where it has its effect. In case the drug does not end up in the right location, i.e. the lung, there may arise problems for the patient.

Due to the increased interest in dry powder inhalation formulations, other concepts have been

investigated include the use of anhydrous β -lactose as a carrier or agglomerates of the active component without carrier. These concepts have not led to satisfactory results either.

5 It is therefore the object of the present invention to provide an improved carrier material for dry powder inhalation formulations.

 In the research that led to the present invention it was found that spray-dried carrier material
10 consists of spherical particles, which show excellent flow characteristics, but that spray dried products may contain amorphous material which can undergo crystallisation in the presence of moisture. When this
15 ingredient, such as a drug, it may become bound and will not detach upon inhalation. The presence of amorphous material can therefore potentially affect stability and performance of the inhalation formulation, if moisture uptake occurs within the dry powder inhaler. It was found
20 that in order to improve the functionality of spray dried products in dry powder inhalation formulations a crystallisation step should be incorporated into the manufacture of the carrier material. The purpose of the crystallisation step is to remove substantially all, and
25 preferably all the amorphous material present.

 The present invention thus relates to a carrier material, comprising carrier particles that are spherical in nature and contain substantially no or no amorphous material.

30 Such carrier material is for example obtainable by a method comprising the steps of:

 a) providing a carrier base material consisting of spherical carrier particles; and

 b) crystallising the carrier base material in
35 order to remove amorphous material present in the particles to obtain the carrier material.

 The provision of the spherical carrier base material can be achieved by spray drying a starting

material to obtain a powder that consists of substantially spherical particles of the carrier material that still contain amorphous material. A suitable method for obtaining such carrier base material is described in
5 EP-239 172, which is incorporated herein by reference. In summary, the method described therein comprises feeding a slurry of crystalline α -lactose hydrate in a saturated lactose solution to a spray drier and drying the same, wherein the selection of the ratio between the amounts of
10 crystalline material and dissolved lactose in the slurry determines the ratio between the amounts of crystalline and amorphous lactose in the spray dried product. The person skilled in the art of spray drying can modify the process conditions to obtain a suitable spray dried
15 product based on his common general knowledge of spray drying.

The present invention thus provides a spray dried product with substantially no or no amorphous material, by virtue of which it has excellent flow
20 properties and is stable with regard to air moisture.

Preferred carrier materials are those known to be useful for dry powder inhalation formulations. In particular these are monosaccharides such as glucose, fructose, mannose etc. and the polyols derived therefrom
25 like sorbitol, mannitol etc. , disaccharides such as lactose, maltose, sucrose and their derivatives such as lactitol, maltitol, and oligo- and polysaccharides such as dextrans and starches.

The carrier base material for the spray drying
30 process can be one of the above mentioned materials or combinations of these. Preferably, the carrier base material is a crystalline carrier base material, in particular a crystalline sugar such as glucose, fructose, sucrose or mannitol and most preferably the carrier base
35 material is lactose.

The amorphous content of the spray dried product (base powder) is generally within the range 0.5% to 50%. The amorphous material present in the spray dried

powder particles can then be crystallised by any suitable method. A particularly preferred method yielding good results is the use of a fluid bed dryer using suitable conditions with regard to temperature and relative humidity which allow the amorphous material to crystallise. Suitable temperature conditions are a temperature of 20 to 100°C, preferably 30 to 90°C, more preferably 40 to 80°C, even more preferably 50 to 70°C, most preferably 60°C in combination with a suitable relative humidity of 80% to 10%, preferably 70 to 15%, more preferably 60 to 20%, even more preferably 50 to 25%, further more preferably 40 to 30%, most preferably 35%.

The carrier material of the invention produced for the purpose of dry powder inhalation has a particle size typically between 1 μm and 400 μm . Preferably, the particle size is between 40 μm and 300 μm . Typically, at least 90% of the particles are within this latter range.

The present invention furthermore relates to a dry powder inhalation formulation which contains a carrier material of the invention and at least one pharmacologically active component. The active component may be selected from the group consisting of steroids, sympathomimetics, mucolytics, proteins, peptides, sodium cromoglycate or from the group consisting of hypnotics, sedatives, analgesics, anti-inflammatory agents, anti-histamines, anticonvulsants, muscle relaxants, anti-spasmodics, anti-bacterials, antibiotics, cardiovascular agents and hypoglycaemic agents.

Preferably the active component is budesonide or alternatively sodium cromoglycate.

The performance of carrier material of the present invention is demonstrated in the following examples that are given for illustration purposes only.

EXAMPLES**EXAMPLE 1****Comparison to α -lactose monohydrate**

α -Lactose monohydrate is commonly used in dry powder inhalation formulations. It has generally a good performance, but over time the problems described in the specification, i.e. crystallisation upon contact with air humidity and thus decreased stability and performance, may occur.

10 To demonstrate the performance of the invention in comparison to α -lactose monohydrate (standard crystal form of lactose), non-pretreated α -lactose monohydrate and a selected size fraction of the carrier material of the invention were used in an inhalation formulation. As 15 a second control standard spray dried lactose was used.

A suspension of a fine milled α -lactose monohydrate powder in an aqueous lactose solution was spray dried, resulting in a spray dried powder with approximately 20% amorphous lactose. This represents the 20 standard spray dried lactose.

To prepare the carrier material of the invention, the amorphous lactose in the spray dried powder obtained above was then crystallised by a treatment in a fluid bed dryer at a temperature of 60°C 25 and a relative humidity of 35 % to obtain a powder having 90% of the particles in the particle size range from 40-300 μ m.

α -Lactose monohydrate was obtained from DMV International, Veghel, the Netherlands.

30 Budesonide was used as the active component, with an active ingredient to carrier ratio of 1:62.5. The formulations were prepared using a tumble mixer. The budesonide concentrations were determined by UV spectroscopy.

35 The performance of the formulations was assessed in vitro using the multi-stage liquid impinger, with the method described in the USP24. The device used was a multidose inhaler, utilising a reservoir system.

The results obtained are shown in table 1 as a percentage (%) of the nominal dose. The fraction "Stage 3 + 4 + filter" is considered as the fraction reaching the lungs.

5 Table 1

	% deposition of budesonide		
	-lactose monohydrate	carrier of the invention	standard spray dried lactose
inhaler	19.2	7.6	9.1
throat	14.4	26.0	33.5
stage 1	34.2	37.0	44.1
stage 2	3.1	3.5	3.7
stage 3+4+filter	30.7	29.6	15.0
total recovered	101.6	104.7	105.4

15

EXAMPLE 2

Comparison between carrier material of the invention and standard spray dried material

Analogous to the method described in Example 1, two inhalation preparations of sodium cromoglycate using carrier material of the invention and standard spray dried material were prepared and tested. Table 2 shows the results.

25 Table 2

	% deposition of cromoglycate	
	carrier of the invention	standard spray dried material
inhaler	6.1	4.2
throat	26.0	21.0

stage 1	39.9	50.5
stage 2	7.5	8.9
stage 3+4+filter	17.1	13.6
total recovered	96.4	98.3

5

EXAMPLE 3Comparison between carrier material of the invention and standard spray dried material

10 Two inhalation preparations of budesonide were prepared using carrier material of the invention and standard spray dried material, wherein the carrier material of the invention was prepared at varying spray drying conditions. The preparation and testing of these

15 formulations was as described in Example 1. The deposition values given in Table 3 are the average of two determinations.

Table 3

20

	% deposition of budesonide			
	40°C/55%RH	60°C/35%RH	74°C/22%RH	standard spray dried lactose
inhaler	8.4	7.6	8.8	9.1
throat	23.8	26.0	27.6	33.5
stage 1	38.4	37.0	37.2	44.1
25 stage 2	3.7	3.5	3.8	3.7
stage 3+4+filter	28.8	29.6	20.9	15.0
total recovered	103.1	104.7	98.3	105.4

CLAIMS

1. Carrier material for use in dry powder inhalation formulations, comprising carrier particles
5 that are spherical in nature and contain no amorphous material.

2. Method for the preparation of a carrier material for use in dry powder inhalation formulations, comprising the steps of:

10 a) providing a carrier base material consisting of spherical carrier particles; and

b) crystallising the carrier base material in order to remove amorphous material present in the particles to obtain the carrier material.

15 3. Method as claimed in claim 2, wherein the provision of the spherical carrier base material is achieved by spray drying a starting material under conditions that lead to a powder that consists of substantially spherical particles of the carrier material
20 that still contain amorphous material.

4. Method as claimed in claim 2 and 3, wherein the spherical carrier base material is produced by feeding a slurry of crystalline α -lactose hydrate in a saturated lactose solution to a spray drier and drying
25 the same.

5. Method as claimed in claims 2-4, wherein step b) is performed at a temperature between 20 and 100°C, preferably between 30 and 90°C, more preferably between 40 and 80°C, even more preferably between 50 and
30 70°C, most preferably at 60°C in combination with a relative humidity of 80% to 10%, preferably 70 to 15%, more preferably 60 to 20%, even more preferably 50 to 25%, further more preferably 40 to 30%, most preferably 35%.

35 6. Method according to claims 1-5, wherein the carrier material is produced of a monosaccharide, in particular glucose, fructose, mannose, or of the polyols derived therefrom, in particular sorbitol, mannitol.

7. Method according to claims 1-5, wherein the carrier material is produced of a disaccharide, in particular lactose, maltose, sucrose, or their polyols, in particular lactitol, mannitol.

5 8. Method according to claims 1-5, wherein the carrier material is produced of oligosaccharides or polysaccharides, in particular dextrans and starches.

9. Method according to claims 1-7, where the material is produced of a crystalline sugar, in
10 particular glucose, fructose, mannitol, or sucrose.

10. Method according to claims 1-7, wherein the material is produced of lactose.

11. Carrier material for use in dry powder inhalation formulations obtainable by a method as claimed
15 in claims 2-10.

12. A carrier material according to claim 11, wherein the particle size of the material is between 1 μm and 400 μm .

13. A carrier material according to claim 12,
20 wherein the particle size of the material is between 40 μm and 300 μm .

14. A dry powder inhalation formulation which contains a carrier material according to claims 1 or 11-13 and at least one pharmacologically active component.

25 15. A dry powder inhalation formulation according to claim 14, in which the active component is selected from the group consisting of steroids, sympathomimetics, mucolytics, proteins, peptides, sodium cromoglycate.

30 16. A dry powder inhalation formulation according to claim 14, in which the active component is selected from the group consisting of hypnotics, sedatives, analgesics, anti-inflammatory agents, anti-histamines, anticonvulsants, muscle relaxants,
35 anti-spasmodics, anti-bacterials, antibiotics, cardiovascular agents and hypoglycaemic agents.

17. A dry powder inhalation formulation according to claim 14, wherein the active component is budesonide.

18. A dry powder inhalation formulation
5 according to claim 14, wherein the active component is sodium cromoglycate.

INTERNATIONAL SEARCH REPORT

Int'l Application No

EP 01/08395

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/14 A61K47/26 A61K31/58 A61K31/35 A61P11/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, MEDLINE, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 239 172 A (DMV CAMPINA BV) 30 September 1987 (1987-09-30) cited in the application abstract examples 1-3 claims 1-6	2-18
X	US 5 376 386 A (GANDERTON DAVID ET AL) 27 December 1994 (1994-12-27) abstract column 1, line 7 -column 4, line 68 examples 1-7 claims 1-7	2-18



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *G* document member of the same patent family

Date of the actual completion of the international search

14 December 2001

Date of mailing of the international search report

02/01/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Taylor, G.M.

INTERNATIONAL SEARCH REPORT

International Application No.

EP 01/08395

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 874 063 A (TROFAST EVA ET AL) 23 February 1999 (1999-02-23) abstract column 1, line 11 -column 4, line 56 examples 1-12 claims 1-20 ---	2-18
X	US 5 254 330 A (GANDERTON DAVID ET AL) 19 October 1993 (1993-10-19) abstract column 1, line 4 -column 4, line 47 examples 1,2 claims 1-14 ---	2-18
X	WO 98 31346 A (MASSACHUSETTS INST TECHNOLOGY ; PENN STATE RES FOUND (US)) 23 July 1998 (1998-07-23) abstract examples 1-14 claims 1-38 -----	2-18

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1

Present claim 1 relates to a product defined by reference to a desirable characteristic or property, namely

the carrier particles are spherical in nature;
the carrier particles contain no amorphous material.

The claims cover all products having this characteristic or property, whereas the application provides support within the meaning of Art. 6 PCT and/or disclosure within the meaning of Art. 5 PCT for only a very limited number of such products, namely one specific method for the preparation of a lactose-based carrier material. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Independent of the above reasoning, the claims also lack clarity (Art. 6 PCT). An attempt is made to define the product by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely the subject-matter of claims 2-18 (excluding any dependencies on claim 1).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Inter. Application No
PCT/JP 01/08395

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 0239172	A	30-09-1987	NL	8600731 A	16-10-1987
			DE	3784260 D1	01-04-1993
			DE	3784260 T2	16-09-1993
			EP	0239172 A2	30-09-1987
			JP	62265295 A	18-11-1987
			US	4802926 A	07-02-1989
<hr/>					
US 5376386	A	27-12-1994	AT	98487 T	15-01-1994
			DE	69100792 T2	14-04-1994
			NO	913731 A	21-11-1991
			AU	635616 B2	25-03-1993
			AU	7155991 A	21-08-1991
			CA	2049302 A1	25-07-1991
			DE	69100792 D1	27-01-1994
			EP	0464171 A1	08-01-1992
			WO	9111179 A1	08-08-1991
			GB	2240337 A , B	31-07-1991
			HU	59821 A2	28-07-1992
			IE	910222 A1	31-07-1991
			JP	3100626 B2	16-10-2000
			JP	4504427 T	06-08-1992
			PT	96567 A	15-10-1991
			US	5254330 A	19-10-1993
<hr/>					
US 5874063	A	23-02-1999	US	5637620 A	10-06-1997
			US	5562923 A	08-10-1996
			AT	137671 T	15-05-1996
			AT	208613 T	15-11-2001
			AU	662519 B2	07-09-1995
			AU	1534792 A	17-11-1992
			BG	61474 B1	30-09-1997
			BG	98147 A	15-11-1994
			CA	2106975 A1	12-10-1992
			CZ	9302116 A3	13-04-1994
			DE	69210601 D1	13-06-1996
			DE	69210601 T2	02-10-1996
			DK	580648 T3	16-09-1996
			EE	2970 B1	17-06-1996
			EP	0508969 A1	14-10-1992
			EP	0580648 A1	02-02-1994
			EP	0680752 A2	08-11-1995
			ES	2086733 T3	01-07-1996
			FI	934429 A	08-10-1993
			GR	3020602 T3	31-10-1996
			HK	52497 A	02-05-1997
			HU	65095 A2	28-04-1994
			IE	921144 A1	21-10-1992
			JP	6506454 T	21-07-1994
			KR	216384 B1	16-08-1999
			NO	933575 A	06-10-1993
			PL	168232 B1	31-01-1996
			RO	115779 B1	30-06-2000
			RU	2112507 C1	10-06-1998
			WO	9218110 A1	29-10-1992
			SG	43180 A1	17-10-1997
			SK	108893 A3	09-03-1994
			AT	199828 T	15-04-2001
			AU	681186 B2	21-08-1997

INTERNATIONAL SEARCH REPORT

Inter. Application No

P 01/08395

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5874063	A	AU 7626494 A	21-03-1995
		BR 9407320 A	16-04-1996
		CN 1133004 A , B	09-10-1996
		CN 1195523 A	14-10-1998
		CZ 9600544 A3	15-05-1996
		DE 69426934 D1	26-04-2001
		DE 69426934 T2	13-09-2001
		DK 717616 T3	11-06-2001
		EE 3203 B1	15-04-1996
		EG 20779 A	29-02-2000
		EP 0717616 A1	26-06-1996
		ES 2156158 T3	16-06-2001
		FI 960869 A	26-02-1996
		HU 74000 A2	28-10-1996
<hr/>			
US 5254330	A	19-10-1993	AT 98487 T
			AU 635616 B2
			AU 7155991 A
			CA 2049302 A1
			DE 69100792 D1
			DE 69100792 T2
			EP 0464171 A1
			WO 9111179 A1
			GB 2240337 A , B
			HU 59821 A2
			IE 910222 A1
			JP 3100626 B2
			JP 4504427 T
			NO 913731 A
			PT 96567 A
			US 5376386 A
<hr/>			
WO 9831346	A	23-07-1998	US 5855913 A
			EP 0954282 A1
			WO 9831346 A1
			US RE37053 E1
			US 5985309 A
<hr/>			